151 related articles for article (PubMed ID: 18813354)
21. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
[TBL] [Abstract][Full Text] [Related]
22. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
23. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
24. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
25. [Von Hippel-Lindau syndrome - a case report].
Figlus M; Kaczorowska B; Jaskólski DJ; Kępczyński Ł
Pol Merkur Lekarski; 2018 May; 44(263):248-252. PubMed ID: 29813043
[TBL] [Abstract][Full Text] [Related]
26. Von hippel-lindau disease: a genetic and clinical review.
Haddad NM; Cavallerano JD; Silva PS
Semin Ophthalmol; 2013; 28(5-6):377-86. PubMed ID: 24138046
[TBL] [Abstract][Full Text] [Related]
27. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
Esteban MA; Tran MG; Harten SK; Hill P; Castellanos MC; Chandra A; Raval R; O'brien TS; Maxwell PH
Cancer Res; 2006 Apr; 66(7):3567-75. PubMed ID: 16585181
[TBL] [Abstract][Full Text] [Related]
28. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
29. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.
Speisky D; Duces A; Bièche I; Rebours V; Hammel P; Sauvanet A; Richard S; Bedossa P; Vidaud M; Murat A; Niccoli P; Scoazec JY; Ruszniewski P; Couvelard A;
Clin Cancer Res; 2012 May; 18(10):2838-49. PubMed ID: 22461457
[TBL] [Abstract][Full Text] [Related]
30. Action of hypoxia-inducible factor in liver and kidney from mice with Pax8-rtTA-based deletion of von Hippel-Lindau protein.
Mathia S; Paliege A; Koesters R; Peters H; Neumayer HH; Bachmann S; Rosenberger C
Acta Physiol (Oxf); 2013 Mar; 207(3):565-76. PubMed ID: 23384425
[TBL] [Abstract][Full Text] [Related]
31. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity.
Lewis MD; Roberts BJ
Oncogene; 2004 Mar; 23(13):2315-23. PubMed ID: 14691445
[TBL] [Abstract][Full Text] [Related]
32. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
Rankin EB; Tomaszewski JE; Haase VH
Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
[TBL] [Abstract][Full Text] [Related]
33. Papillary cystadenoma of the epididymis.
Odrzywolski KJ; Mukhopadhyay S
Arch Pathol Lab Med; 2010 Apr; 134(4):630-3. PubMed ID: 20367315
[TBL] [Abstract][Full Text] [Related]
34. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
35. A detailed immunohistochemical analysis of 2 cases of papillary cystadenoma of the broad ligament: an extremely rare neoplasm characteristic of patients with von hippel-lindau disease.
Brady A; Nayar A; Cross P; Patel A; Naik R; Lee S; Kaushik S; Barton D; McCluggage WG
Int J Gynecol Pathol; 2012 Mar; 31(2):133-40. PubMed ID: 22317868
[TBL] [Abstract][Full Text] [Related]
36. Case of parotid mucoepidermoid carcinoma: Expanding the spectrum of von Hippel-Lindau-related neoplasms.
Berger MH; Kerr DA; Rangel Filho AE; Sargi ZB
Head Neck; 2017 Mar; 39(3):E51-E54. PubMed ID: 28006088
[TBL] [Abstract][Full Text] [Related]
37. Developmental effects of von Hippel-Lindau gene deficiency.
Vortmeyer AO; Yuan Q; Lee YS; Zhuang Z; Oldfield EH
Ann Neurol; 2004 May; 55(5):721-8. PubMed ID: 15122713
[TBL] [Abstract][Full Text] [Related]
38. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
39. Aggressive papillary tumor of middle ear/temporal bone and adnexal papillary cystadenoma. Manifestations of von Hippel-Lindau disease.
Gaffey MJ; Mills SE; Boyd JC
Am J Surg Pathol; 1994 Dec; 18(12):1254-60. PubMed ID: 7977949
[TBL] [Abstract][Full Text] [Related]
40. Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma.
Zhou J; Wang J; Li N; Zhang X; Zhou H; Zhang R; Ma H; Zhou X
Pathol Int; 2010 Jun; 60(6):452-8. PubMed ID: 20518900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
